Clinical Trials Logo
NCT number NCT00976105
Study type Interventional
Source GlaxoSmithKline
Status Completed
Phase Phase 1
Start date September 22, 2009
Completion date March 9, 2010

Clinical Trial Summary

The overall purpose of this study is to see whether the drug is safe and well tolerated when given to overweight or obese but otherwise healthy volunteers for 10 days. Up to 4 groups of people will be given the drug at variable strengths. The blood levels of the drug will be measured and the effects on mood and cognition (the mental processes involved in awareness, learning and judgement) will be assesed.

Clinical Trial Description

This study is to test a new drug which may be used for treating eating behaviour and patterns that some overweight and obese patients find difficult to control. The drug works by inhibiting the effects of messenger molecules called opioids, e.g. endorphins. These opioids are naturally produced within the human body and control hunger, thirst, and the pleasurable feelings we relate to eating food. The drug attaches to opioid binding sites in the brain, known as mu-opioid receptors; this blocks the natural effect of opioids which may reduce the craving to eat fatty or sugary foods. Single doses of the drug have been given to humans and showed it was safe. Now the drug will be given every day for 10 days to check that the drug is safe and tolerated when given repeatedly. The study is in two parts:

Part A: people will receive a sleeping tablet to make them sleepy (or a dummy drug) and will complete some questionnaires and simple tests including computer exercises to test the effect of this tablet on mood and cognition. This information will be used to help judge what is happening in Part B.

Part B: requires staying in the unit for 10 days to receive a tablet every day and complete questionnaires and other tests to check for any mood and cognitive changes. Various other assessments will include effects on eating behaviour, pain measures and changes in body composition (content of fat, muscle and water).

Study Design

Related Conditions & MeSH terms

See also
  Status Clinical Trial Phase
Recruiting NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Completed NCT02235961 - Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects Phase 1
Completed NCT03195712 - Metabolically Healthy Obesity: Correlations Between BMI and Metabolic Syndrome Biomarkers N/A
Recruiting NCT00341406 - Fat Cell Size in Insulin Resistance N/A
Recruiting NCT02918279 - Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity Phase 3
Completed NCT00494767 - Investigation Of Weight Loss And Body Composition Changes After Dosing With Either Placebo Or One Of Two Active Drugs Phase 1
Completed NCT01222793 - Effects of Antipsychotics on Eating and Food Craving in People With Schizophrenia N/A
Completed NCT01967563 - Study of the Effect of a Very-Low-Carbohydrate Diet on Energy Expenditure N/A
Completed NCT00535600 - Effects of Bariatric Surgery on Insulin N/A
Not yet recruiting NCT03104205 - MOWI Home-Based Pilot N/A
Recruiting NCT03130244 - Endoscopic Procedure for Jejunal to Ileal Diversion to Treat Type 2 Diabetes N/A
Recruiting NCT03104192 - MOWI Research Pilot N/A
Not yet recruiting NCT03232762 - Effects of Diet on Pregnancy Outcome and Child Obesity N/A
Not yet recruiting NCT03251833 - The Impact of Obesity on Maternal and Perinatal Outcomes N/A
Not yet recruiting NCT03238794 - Bariatric Surgery Versus Diet Alone in the Bile Acid Pathway and Weight Loss N/A
Not yet recruiting NCT03036800 - Saxenda in Obesity Services (STRIVE Study) Phase 4
Not yet recruiting NCT03047018 - Open Trial Obesity CHANGE Program ASD N/A
Not yet recruiting NCT03112824 - Functional Assessment of Ashwagandaha Root Extract During Weight Loss Phase 3
Not yet recruiting NCT03236337 - Effectiveness of MOVI Interventions on Adiposity, Cognition and Subclinical Atherosclerosis: MOVI-daFit! N/A
Not yet recruiting NCT02957539 - Financial vs. Non-Financial Rewards for Weight Loss and Weight Maintenance N/A